BiotechTube
Home/AdjuTec Pharma/Pål Rongved
PR

Pål Rongved

Founder, Professor Emeritus (University of Oslo), Largest Shareholder

AdjuTec Pharma

Therapeutic Areas

Infectious DiseaseAntimicrobial Resistance

AdjuTec Pharma Pipeline

DrugIndicationPhase
APC301Multidrug-resistant bacterial infections (MBL & SBL-producing Enterobacterales)Phase 1
APC302Multidrug-resistant bacterial infectionsPreclinical
APC148-based combinationsOther serious bacterial infectionsResearch
Fungal resistance breakersInvasive fungal diseasesResearch

Leadership Team at AdjuTec Pharma

Ø
Øy
Board Chair
View full AdjuTec Pharma profile